4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• 4D Molecular Therapeutics' stock has been assigned a "Sell (D-)" rating by Weiss Ratings, indicating concerns about the company's financial health.
• Despite Weiss Ratings' negative outlook, 8 other analysts have rated the stock as a "Buy," with an average target price of $30.40.
• In its latest quarterly earnings, 4D Molecular Therapeutics reported a loss of ($0.98) earnings per share, which was below analysts' expectations, highlighting ongoing financial challenges.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Several other equities analysts also recently commented on FDMT. Chardan Capital restated a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Roth Capital decreased their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Trading Down 0.1%

4D Molecular Therapeutics stock opened at $6.80 on Friday. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $17.41. The firm has a market capitalization of $317.56 million, a price-to-earnings ratio of -1.93 and a beta of 2.85. The firm has a 50 day moving average of $5.75 and a 200 day moving average of $4.37.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%. On average, analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. Velan Capital Investment Management LP purchased a new stake in 4D Molecular Therapeutics during the fourth quarter valued at approximately $56,000. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. Los Angeles Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $42,000. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in 4D Molecular Therapeutics in the first quarter worth $41,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.